9/22/2010

Ranbaxy Laboratories gained exclusive rights to sell a generic version of Eisai's Alzheimer's drug Aricept. The FDA said Teva Pharmaceutical Industries, which has approval to sell the drug, must wait 180 days before competing with Ranbaxy.

Full Story:
Bloomberg

Related Summaries